Lucentis
Lucentis and Avastin equal in efficacy
July 19, 2013Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin
Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …
New price and data changes NICE view on Lucentis
January 4, 2013Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis
A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
ABPI slams NHS findings
October 18, 2012Sales and Marketing ABPI, Lucentis, NICE, UK
The ABPI has expressed concern at a report by the NHS’s Health and Social Care Information Centre (HSCIC) which suggests …
NICE does Lucentis U-turn
October 5, 2012Sales and Marketing Lucentis, NICE, Novartis, Roche, avastin
NICE has done a U-turn over its previous verdict on Novartis’ Lucentis, now recommending the drug in draft guidance to …
Novartis to file for new Lucentis indication
September 7, 2012Lucentis, Novartis, macular edema, macular oedema, ophthamology
Novartis is set to file eye treatment Lucentis for a new indication. The firm will submit Lucentis (ranibizumab) to the …
New Avastin data could be bad news for Lucentis
August 14, 2012Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
Lucentis gains new licence in the US
August 13, 2012Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD
Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
Sue NHS to ensure access to drugs, says NICE chief
August 6, 2012Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology
The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …
Novartis ponders Lucentis price cut in UK
May 8, 2012Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access
Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …
Novartis right to challenge NHS on Avastin use – ABPI chief
April 27, 2012Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD
The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …
GMC won’t relax off-label prescribing guidelines
April 25, 2012Sales and Marketing GMC, Lucentis, Novartis, Roche, avastin, off label, off-label
The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …
Charity challenges government on Avastin for wet AMD
April 24, 2012Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …
GMC guidance on off-label drug use delayed
March 19, 2012Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing
The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …
Bayer eye drug succeeds in long-term study
February 21, 2012Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD
Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition. The Phase III …
